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Abstract
Creation of an effective vaccine for HIV has been an elusive goal of the scientific community for almost 30 years.
Neutralizing antibodies are assumed to be pivotal to the success of a prophylactic vaccine but previous attempts to make
an immunogen capable of generating neutralizing antibodies to primary ‘‘street strain’’ isolates have resulted in responses
of very limited breadth and potency. The objective of the study was to determine the breadth and strength of neutralizing
antibodies against autologous and heterologous primary isolates in a cohort of HIV-1 infected Nigerians and to characterize
envelopes from subjects with particularly broad or strong immune responses for possible use as vaccine candidates in
regions predominated by HIV-1 CRF02_AG and G subtypes. Envelope vectors from a panel of primary Nigerian isolates were
constructed and tested with plasma/sera from the same cohort using the PhenoSense HIV neutralizing antibody assay
(Monogram Biosciences Inc, USA) to assess the breadth and potency of neutralizing antibodies. The immediate goal of this
study was realized by the recognition of three broadly cross-neutralizing sera: (NG2-clade CRF02_AG, NG3-clade CRF02_AG
and NG9- clade G). Based on these findings, envelope gp140 sequences from NG2 and NG9, complemented with a gag
sequence (Clade G) and consensus tat (CRF02_AG and G) antigens have been codon-optimized, synthesized, cloned and
evaluated in BALB/c mice. The intramuscular administration of these plasmid DNA constructs, followed by two booster DNA
immunizations, induced substantial specific humoral response against all constructs and strong cellular responses against
the gag and tat constructs. These preclinical findings provide a framework for the design of candidate vaccine for use in
regions where the HIV-1 epidemic is driven by clades CRF02_AG and G.
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Introduction
Globally, approximately 33.4 million individuals now live with
human immunodeficiency virus type-1 (HIV-1) infection, 22
million of whom reside in Sub-Saharan Africa. Thus, Sub-
Saharan Africa remains the region most heavily affected by HIV.
In 2008, sub-Saharan Africa accounted for 67% of HIV infections
worldwide, 68% of new HIV infections among adults and 91% of
new HIV infections among children. The region also accounted
for 72% of the world’s AIDS-related deaths in 2008 [1]. The
development of a vaccine to prevent HIV infection is a global
health priority. Previous clinical efficacy trials failed to support the
continued development of recombinant gp120 (rgp120) as a
candidate HIV vaccine since they were unable to elicit consistent
T-cell or protective antibody responses [2,3,4,5,6]. However, the
partial efficacy shown by the recent RV144 trial, the RV144
largest HIV vaccine clinical trial to date, has rekindled interest in
rgp120 subunit vaccines [7]. The AIDSVAX B/E rgp120 vaccine
used in the RV144 trial in Thailand is considered inappropriate
for clinical trials in sub-Sahara Africa where the genetic diversity
of group M HIV-1 is highest and where the epidemic is driven by
HIV-1 clades different from those found in Thailand as well as to a
lesser extent HIV-2 [8].
HIV-1 subtypes A and C have accounted for the majority of
infections in the central and Southern region of Africa, whereas
HIV-1 subtypes A, G and O have predominated in the Western
regions of Africa. Nigeria is also experiencing a unique HIV-1
epidemic consisting of two highly divergent subtypes: CRF02_AG
and G [8,9]. The CRF02_AG is also most prevalent in West
Africa and Central West African countries [10,11,12], therefore,
Nigeria’s success in promoting efforts towards HIV/AIDS
prevention, treatment and vaccine development will be important
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antibodies to neutralize primary isolates is at least partially related
to the genetic closeness of the primary virus to the immunizing
strain and geographic preference of many HIV subtypes [13,14].
Accordingly, in order to contend with the high HIV sequence
variation, there is great interest in selecting region-specific
immunogens to maximize the likelihood of protection against
local strains in the geographical area where the vaccine is intended
for use. This kind of approach is adequate to additionally consider
co-receptor usage, neutralization susceptibility, or neutralization
potency of the serum from the individual from whom the isolate
was obtained.
With over 30 years of active research, an effective HIV-1
vaccine that can be used for prophylactic or therapeutic purposes
in humans has not been identified. The introduction of highly
active antiretroviral therapies (HAART) has significantly reduced
HIV morbidity and mortality [15]. HAART therapies are only
effective in delaying the onset of disease or progression to AIDS
but cannot eradicate the virus and the epidemic. The most
effective way of intervention against viral diseases is by
vaccination. With this subtype scenario, HIV/AIDS vaccine
constructs would have to be developed against indigenous
subtypes. It is, therefore, likely that HIV-1 subtype surveillance
will remain an important component of vaccine design; as viral
epitopes evolve, novel epitopes will need to be considered for
eliciting potent antiviral immune responses.
It has long been believed that neutralizing antibodies are key to
the success of a prophylactic vaccine. However, the enormous
variability together with the extraordinary capability of HIV to
escape the immune system impeded the successful development of
protective env-based immunogens and cross-neutralization is
hardly observed and predominantly restricted to closely related
isolates [16,17] . This observation has resulted in the generation of
region-specific immunogens to maximize the likelihood of
protection against local strains. This study was carried out to
characterize viruses from HIV-1
+ patients in Nigeria, for the
presence of broadly neutralizing antibodies against subtype
regional isolates. A selection of envelop sequences derived from
primary HIV isolates of the Nigerian cohort was used for
neutralization studies and cross neutralization was evaluated
within the cohort testing pseudo-typed reporter viruses against
individual plasma/sera samples. Envelopes of CRF02_AG and G,
which were capable of stimulating broadly neutralizing antibodies,
were further characterized. The overall ambition towards
developing a regional vaccine candidate prompted us to expand
the set of test antigens in order to include epitopes derived
from various viral gene products offering different immune
stimulatory capacities, necessary to activate different arms of the
immune system. Therefore, supplementing the env candidates, gag
and consensus tat genes were included in the set of antigens, which
were codon-optimized and synthesized for use in a DNA-
immunization study in mice in order to determine their
immunogenicity and suitability as possible future vaccine
candidates.
Materials and Methods
Study population
Blood samples were randomly collected from 23 individuals
enrolling in the Nigerian national antiretroviral therapy program
(Table 1). Blood specimens were separated by centrifugation into
plasma and peripheral blood mononuclear cells (PBMC) using BD
VacutainerH CPT
TM Tubes (BD Company, NJ USA). Plasma and
PBMC were stored at 280uC and the plasma were used to build
viral env vectors and test for neutralizing antibodies according to
established standard operating procedures in the CLIA/CAP
certified Clinical Reference Laboratory (MCRL) at Monogram
Biosciences, San Francisco, California. Samples were collected as
part of the national HIV treatment program and signed informed
consent was obtained from all subjects. The program was
approved by the Nigerian federal ministry of Health.
Neutralization assay
The PhenoSense
TM HIV assay [18] initially developed to
evaluate protease inhibitors and reverse transcriptase inhibitors
was used in this study to measure virus-antibody neutralization.
Briefly, HIV genomic RNA was isolated from virus stocks or
plasma. DNA spanning the open reading frame of gp160 was
amplified by reverse transcription PCR using forward and reverse
primers located immediately upstream and downstream of the env
initiation and termination codons, respectively. env PCR products
were digested and ligated to compatible ends in an expression
vector (pCXAS), expanded by transformation in competent
Escherichia coli cells and plasmid DNA was purified from bacterial
cultures. Virus particles containing patient virus Env proteins were
produced by co-transfecting HEK293 cells (HEK293 cells:
received from ATCC (commercial source: LGC Standards)
(ATCCH Number: CRL-1573T, reference: [19], PubMed:
886304) with env libraries plus an env
2 HIV genomic vector that
contains a firefly luciferase indicator gene. The HIV-1 genomic
vector is replication defective and contains a luciferase expression
cassette within a deleted region of the HIV envelope gene.
Recombinant viruses pseudotyped with patient-derived virus Env
proteins were harvested 48 h post-transfection and incubated for
1 h at 37uC with serial fourfold dilution of heat-inactivated patient
plasma samples. U87 cells (U87: received from ATCC (commer-
cial source: LGC Standards) (ATCCH Number: HTB 14T,
reference: [20] , PubMed: 4313504) that express CD4 plus the
CCR5 and CXCR4 co-receptors were inoculated with virus-
plasma dilutions. Virus infectivity was determined 72 h post
inoculation by measuring the amount of luciferase activity
expressed in infected cells by comparing the amount of luciferase
activity produced in the presence of test serum/plasma to the
amount of luciferase activity produced in absence of test serum/
plasma. Neutralizing activity was displayed as the percent
inhibition of viral replication (luciferase activity) at each antibody
dilution compared to an antibody negative control [21]: %
inhibition={12[(luciferase with antibody/luciferase without an-
tibody)}6100. Titers were calculated as the reciprocal of the
plasma dilution conferring 50% inhibition (IC50) (Figure 1).
Test Viruses and Plasmas
A panel of recombinant viruses was prepared from patient
plasma collected from Nigeria and where classified as Group M,
subtype CRF02_AG and G [18,21]. The same sera/plasma used
to isolate virus was also used for neutralization tests with the
autologous isolate as well as with heterologous isolates from the
same study group. Additionally, control viruses NL4-3, JR-CSF
and amphotropic Murine Leukemia Virus envelope (aMLV) were
tested with the sera. NL4-3 is a T-cell line adapted isolate that is
extremely neutralization-sensitive and is used as a control to detect
the presence of even low amounts of neutralizing antibody in
samples. JR-CSF is a minimally passaged R5 tropic virus, and is
less sensitive to neutralization. It is more representative of primary
field isolates than the T-cell line adapted viruses while aMLV is the
specificity control and is tested with every plasma/serum. This
control functions to indicate the presence of non-HIV specific
factors, such as toxicity or serum proteins that may influence
HIV-1 Clade CRF02_AG and G Vaccine Candidate
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virus entry in U87/CD4/CCR5/CXCR4 cells but are not
inhibited by anti-HIV Env antibodies. Scoring of a positive
reaction requires that the IC50 for a serum/plasma be at least
3-fold higher than the IC50 of the same serum with aMLV. Patient
plasma evaluation was started at a dilution of 1:10 in cell culture
medium followed by 10 serial 4-fold dilutions. An equal volume of
recombinant virus stock was added to the diluted plasma/serum
making the final neutralization reaction concentrations as follows:
1:20, 1:80, 1:320, 1:1.280, 1:5.120, 1:20.480, 1:81.920, 1:327.680,
1:1.310.720, 1:5.242.880. U87 cells expressing CD4/CCR5/
CXCR4 or a mixture of cells expressing CD4/CCR5 and
CD4/CXCR4 were added to the reaction following a 1-h
incubation of the serum dilutions and virus at 37uC. Infected cells
were incubated for 3 days and luciferase expression was evaluated
on the final day.
Construction of plasmid DNA immunization constructs
In order to evaluate the immunogenicity of isolates from
individuals who had developed broadly neutralizing activity,
gp140 of two viruses, one belonging to subtype CRF02_AG and
the other belonging to the G-subtype were synthesized, cloned and
evaluated preclinically in BALB/c mice. The ‘Cobra’ vector
pORT1 was selected for DNA delivery because it does not contain
an antibiotic resistance gene making it a candidate vector for
planned future clinical trials. The genes were optimised for
mammalian expression, synthetically generated and sub-cloned
into the pORT1 plasmid. The details of this method have been
described previously [22]. Furthermore, four different DNA-
vaccine prototype constructs based on HIV-1 clade CRF02_AG
and G reading frames (ConcTat NG, gag 203, env NG2 and env
NG9) were evaluated. The gag 203 sequence was derived from an
HIV-1 subtype G infected Nigerian patient while the consensus tat
NG was assembled from sequences derived from seven Nigerian
patients infected with either HIV-1 clade CRF02_AG or G.
Vaccination of mice
Female BALB/c mice (Charles River, Sulzfeld, Germany) were
divided into six groups; each group comprised six animals. At the
age of 8–12 week the BALB/c mice were vaccinated with 100 ug
of each plasmid {pORT ConcTat NG, pORT Gag 203, pORT
Env NG2, pORT Env NG9, pORT gp120 C (positive control),
pORT1a clade (negative control) without adjuvant by intramus-
cular (i.m.) saline injection of 50 ml each in both site tibialis
anterior muscles, followed by two booster vaccination with the
same doses (4 and 7 weeks for first and second booster,
respectively). At the indicated time points, individually earmarked
mice were bled and at last sacrificed. Spleens of three mice were
pooled and tested. Immunological parameters analysed were i)
specific antibody generation as determined by western blotting for
all four inserts and ii) activation of antigen specific T cells as
determined by intracellular INFc-staining of CD8
+ T cells
using FACS and quantification of INFc-producing cells using
ELISPOT.
All experiments on BALB/c mice were conducted in accor-
dance with the legal requirements of local and national authorities
(ethics review by government (via Ethics Committee) of Lower
Franconia, Germany).
Transfection of cells
Human lung carcinoma (NCI-H1299 NCI-H1299, received
from ATCC (commercial source: LGC Standards) (ATCCH
Number: CRL-5803T, reference: [23] PubMed: 1563005) cells
were maintained in Dulbecco’s modified Eagle medium (Invitro-
gen) supplemented with 10% fetal calf serum, 2 mM L-glutamine,
100 IU of penicillin, and 100 mg of streptomycin per milliliter
(PAN Biotech, Aidenbach, Germany) and transfected (using
calcium co-precipitation technique) as previously described [24].
Briefly, 3610
6 NCI-H1299 cells were seeded on 100 mm-
diameter culture dishes, incubated for 24 h and then transfected
with 45 mg of different Nucleobond AX (Macherey-Nagel, Du ¨ren,
Germany) purified plasmid constructs. At 16 h post transfection,
the cell culture supernatant was replaced with fresh medium. Cells
were harvested 48 h after transfection.
Immunoblotting
Total cell lysates were prepared 48 h post transfection using a
triple detergent puffer system (RIPA) which was supplemented
with a cocktail of protease inhibitors (Boehringer CompleteTM
Mini Kit; Mannheim GmbH, Mannheim, Germany). Soluble
protein was prepared and protein concentration was determined
by Bradford assay. 75 mg of proteins were separated by SDS-
PAGE and transferred to nitro-cellulose membranes. Blots were
probed with different concentrations of pooled antisera derived
from vaccinated mice (pre-immune and immune sera). An anti-
mouse IgG AP-conjugated monoclonal antibody was used to
detect specific proteins as described [25].
Table 1. Viruses and plasmas used in antibody neutralization
assays.
Sample
Identifier
Tested in Neutralization
Assay
gp160
Sequenced NT activity
Serum/
Plasma Viral env
NG1 X Weak
NG2 X X X Broad/Strong
NG3 X X Broad/Strong
NG4 X Limited/Weak
NG5 X Limited/Weak
NG6 X X Limited/Weak
NG7 X Limited/Weak
NG8 X Limited/Weak
NG9 X X X Broad/Strong
NG10 X Limited/Weak
NG11 X X Limited/Weak
NG12 X Limited/Weak
NG13 X X x Limited/Weak
NG14 X Limited/Weak
NG15 X Limited/Weak
NG16 X X Limited/Weak
NG17 X X Limited/Weak
NG18 X X x Limited/Weak
NG19 X X x Limited/Weak
NG20 X Limited/Weak
NG21 X Limited/Weak
NG22 X X Limited/Weak
NG23 X X Limited/Weak
doi:10.1371/journal.pone.0023233.t001
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IFNc expression of CD8
+ cells was detected by intracellular
staining followed by FACS analysis. Spleenocytes were stimulated
with 10 mM peptide pools (Mimotopes, Pty Ltd., Australia). The
peptides were reconstituted with 13 ml DMSO resulting in an
average concentration of 125 mg/ml. The pools were constructed
by combining 2 ml of each peptide in RPMI medium. Medium
alone served as the negative control. The peptides were incubated
for 6 h with the cells in medium with Brefeldin A (5 mg/ml) for
the whole incubation time. Intracellular staining was performed as
described [26]. In total, 3610
4 CD8
+ lymphocytes were analyzed
by flow cytometry using a FACS Calibur and CellQuest software
(BD Biosciences, San Jose, CA).
ELISPOT assay
96-well multiscreen MAHA-S45 plates (Millipore, Eschborn,
Germany) were coated with 50 ml of anti-mouse IFNc ab (cat.
no. 554431, BD, Heidelberg, Germany; 1:500 PBS without
Mg
++/Ca
++). ELISPOT assays (for IFNc) were performed as
previously described [26]. The plates were then air dried and
colored spots were counted.
Results
Neutralization Results
The IC50s from neutralization reactions of 23 sera samples are
shown in Figure 1. All sera except one (NG9 with low neutralizing
titres; IC50=79), were negative against the homologous virus
from the same patient blood samples. Seventeen sera were also
negative when tested against the heterologous viruses in the panel.
Nineteen patient samples, however, were positive with NL4-3, a
virus which is very sensitive to the presence of neutralizing
antibodies, indicating that even though the sera may have failed to
cross-neutralize the primary isolates, neutralizing antibodies were
present, as shown by inhibition of the T cell line adapted virus.
Three patient plasma/sera samples showed extensive cross-
neutralization of other primary isolates. These samples are NG2
(n=11), NG3 (n=12) and NG9 (n=15). Although these three
plasma/sera effectively neutralize NL4-3, we do not see a
correlation between magnitude of IC50 against NL4-3 and cross-
neutralization of other isolates. In many cases neutralization titers
against NL4-3 were as high or higher in sera without broad cross-
neutralization activity as in sera with broad cross reactivity.
Several sera exhibited high background activity as shown by IC50s
of .100 against aMLV (Figure 1). Since only a subset of the
samples showed this effect; a general effect associated with cell
toxicity is most probably not the cause of the non-specific
inhibitor. A conceivable reason for the observed effect is the
presence of unknown agents in the plasma samples causing
inhibition of the virus through some unclear mechanisms, notably
affecting NG7, NG10, NG12, NG64, NG21 and NG23. although
the study subjects were assumed to not be on treatment at the time
of the acquisition of the plasma, the presence of the high level
background against all isolates including aMLV suggest that some
may have been. gp160 nucleotide sequences of envelope genes of
isolated virions from each 3 individuals with broad cross-
neutralizing activity and 3 individuals with very low neutralizing
antibody activity were sequenced (data not shown). Two
individuals with broad cross-neutralizing antibodies were infected
with CRF02_AG and one of and G, respectively. Two of the
envelope genes (env NG2 and env NG9) derived from patients
showing broad neutralizing activities belonging to HIV-1 clades
CRF02_AG and one of the individual was infected with a subtype
G virus, were chosen for further analyses using the BALB/c mouse
model in order to evaluate their immunogenicity. To monitor the
amount of neutralising activity that is not mediated by antibodies
directed against HIV-1 env proteins, gag (clade G) and consensus
tat (CRF02_AG and G) were also tested for their ability to
generate humoral and cellular immunity in the same animal
model.
Figure 1. Neutralizing antibody titers of plasmas tested with autologous and heterologous viral envelopes. Plasma samples are from
chronically infected individuals not currently on treatment. Titers are expressed as 1/plasma dilution. Higher numbers indicate greater inhibition
(titer). Green color indicates positive neutralization activity which is significantly greater than inhibition of the specificity control, aMLV. Dashed red
line indicates autologous plasma/virus pair. na=not available.
doi:10.1371/journal.pone.0023233.g001
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immunization in mice
Regarding the humoral immune responses, HIV specific
antibodies were found by western blot after the second
immunisation in animals that received the ConcTat NG and gag
203 and after the third immunisation for all constructs (ConcTat
NG, gag 203, env NG2 and env NG9). The western blots were
performed using lysates of cells transiently transfected with the
corresponding pORT1-antigen expression constructs. No anti-
bodies were detected in the negative control mice (pORT1a clade).
In contrast, the positive control (pORT gp120 C) induced
substantial specific antibodies.
Cellular immune responses in mice
Regarding the cellular immunity, the FACS and ELISPOT
assays demonstrated the presence of very solid Gag-specific CD8
+
T cell responses in mice immunized with pORT Gag 203. This
was confirmed independently by the FACS analysis (Figure 2) and
ELISPOT assay (Figure 3). For these assays mouse spleen cells
were restimulated with overlapping peptides covering the
complete gag 203 gene and separated into two pools, Gag1 and
Gag2. Each of the pool induced positive responses, pool 2 higher
than pool 1, arguing for either at least two CTL epitopes being
present in Gag or one epitope localised at the ‘‘border’’ of the two
pools. Similarly, for the tat gene a set of overlapping peptides
covering the complete sequence (as contained in pORT ConcTat
NG) was used for immunological evaluation assays, revealing only
weak to moderate cellular immunity. The data can be interpreted
firstly as no CTL epitope present (negative FACS data) and
secondly as a very weak T helper response detectable (low ELISpot
results). For the env constructs (pORT Env NG2 and pORT Env
NG9) no cellular immune response could be detected. As expected
the positive control (pORT gp120 C) showed a strong cellular
immune response while no cellular immune response could be
found in the negative control (pORT1a clade) (Figures 2 and 3).
Discussion
Nigeria, with a population of over 140 million people, has the
largest HIV/AIDS epidemic in Africa which is characterized by
two HIV-1 subtypes, CRF02_AG and G [8,9,27]. It has long been
recognized that, although HAART has been shown to be clinically
effective, it does not rid the host of the virus, may be toxic and does
not allow the reconstitution of potentially useful anti-HIV immune
responses in infected patients [28]. A major goal in HIV-related
research remains the identification of a potent prophylactic
vaccine to prevent HIV infection. In this study, neutralizing
antibodies against autologous and heterologous primary HIV-1
isolates were measured and found to be generally of low titer. This
is likely due to the inability of the immune system in these
individuals to efficiently respond to rapidly evolving quasi-species.
Only patient NG9 showed autologous antibody response probably
because cell-derived virus does not accurately reflect the actively
Figure 2. Cellular immune responses induced by the DNA vaccine candidates. Intra-cellular INF gamma (IFNc) staining IFNc production was
measured by FACS analysis after intracellular staining of IFNc). Balb/C mice (n=6 per group) were inoculated IM with (i) pORT ConcTat NG, (ii) pORT
Gag 203 , (iii) pORT Env NG2 , (iv) pORT Env NG9 , (v) pORT gp120 C N54 (positive control), (vi) pORT1a clade (negative control). One week after the
second/third booster immunization, spleen cells were isolated and tested for specific cellular immune responses by measuring IFN-g production after
stimulation with pools of overlapping 15-mer peptides. Shown is the total number of CD8
+ IFNc
+ cells per 30.000 CD8
+ restimulated mouse spleen
cells. A) mice 1–3, B) mice 4–6, C) merged data.
doi:10.1371/journal.pone.0023233.g002
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responses have been difficult to measure because of the technical
challenges associated with the preparation of autologous virus
stocks that are typically obtained from PBMCs [21].
Although neutralizing activity against autologous virus was
generally low, neutralizing activity against isolates from other
members of the study subjects (heterologous virus) was compar-
atively higher particularly NL4-3 (Figure 1). NL4-3 is a laboratory
adapted strain that has presumably lost those virologic factors that
protect against antibody-mediated neutralization in vivo [29]. NL4-
3-specific responses may therefore be a surrogate for the overall
level of HIV-specific neutralizing titers. Despite the generally low
level of neutralizing antibody titers, three plasma did demonstrate
a wide breath of solid cross neutralizing activity against a range of
primary Nigerian viruses with high cross-neutralizing titers as
shown (Figure 1), suggesting that these antibodies may be
protective and could contribute to an effective HIV vaccine. This
corroborates with previous studies showing that certain anti-V3
NAbs can neutralize diverse strains of HIV-1 [30,31,32]. The
ability to cross-neutralize viruses isolated from other individuals as
seen in sera from this study possibly implies that certain individuals
do have neutralizing capabilities that could be taken advantage of
in term of viral evolution and for vaccine design in regions with
HIV-1 CRF02_AG and G epidemic. In addition, the individuals
with broad antibody responses are usually chronically infected and
the antibody breath results from either the ongoing production of
HIV-specific antibodies in response to viral evolution or the
maturation of the antibody response over time. Although the
factors that contribute to the development of broad heterologous
responses remain unclear, it has been speculated that broadly
reactive responses evolve over a longer course of HIV infection
[21,33,34]. Whether this observation reflects antigen-driven
expansion and/or abnormal B-cell activation is unclear. The
immediate goal of this study was realized by finding of three cross-
neutralizing sera and the cloning of viral envelopes from those
sera.
Within the presented study three cross-neutralizing sera have
been identified and the respective virus isolates have been
subjected to continuative preclinical analyses. Envelope gp140
sequences from the three isolates that generated these antisera
have been codon-optimized and two (subtypes CRF02_Ag and G)
were synthesized and cloned for preclinical evaluation in mice. We
believe that this small animal model will provide a rapid and
inexpensive means to improve the safety and effectiveness of
proposed DNA vaccines. Furthermore, mice models have been
shown in this study and others to elicit strong humoral and cell
mediated responses against HIV [22,35]. It is anticipated that
these pre-clinical studies will provide additional experimental
support to the HIV-1 subtypes CRF02_Ag and G vaccine
endeavor and open the way to HIV phase 1 studies of a regional
vaccine.
There is general consensus in the HIV vaccine field that
successful prophylactic HIV-1 vaccine candidates will need to
induce potent broad neutralizing antibodies (Nab) as well as
Figure 3. Cellular immune responses induced by the DNA vaccine candidates (IFNc production was measured using a commercial
ELISPOT assay). Balb/C mice (n=6 per group) were inoculated IM with (i) pORT ConcTat NG, (ii) pORT Gag 203 , (iii) pORT Env MD , (iv) pORT Env
NG9 , (v) pORT gp120 CN54 (positive control), (vi) pORT1a clade (negative control). One week after the second/third booster immunization, spleen
cells were isolated and tested for specific cellular immune responses by measuring IFN-g production after stimulation with pools of overlapping 15-
mer peptides. Shown is the total number of positive (IFNc secreting) cells per 10
6 restimulated mouse spleen cells. A) mice 1–3, B) mice 4–6, C)
merged data.
doi:10.1371/journal.pone.0023233.g003
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comparatively faster and cheaper to develop and are not
dependent on continuous cold-chain disposition for distribution,
they provide a promising avenue for the development of new
vaccination strategies. The technological principle of DNA
vaccines relies on a cloned nucleic acid to encode an antigen
that when taken up is expressed by the host cells in amounts
sufficient to elicit an immune response strong enough to protect
against infectious diseases. Such DNA vaccine plasmids can
include multiple antigens/genes and recombinant DNA technol-
ogy offers an easy way to mix-and-match antigens to produce
novel combinations to stimulate an optimized response
[22,36,37,38].
We assessed the immunogenicity of a panel of primary HIV-1
isolates in BALB/c mice which included, pORT ConcTat NG
(consensus tat clade CRF02_AG and G), pORT Gag 203 (clade
G), pORT Env NG2 (clade G) and pORT Env NG9 (clade
CRF02_AG). The humoral immune response was evaluated based
on sera harvested one week after the first and second booster
immunization. It is encouraging and interesting that all constructs
elicited HIV specific antibody responses which is one major
requirement for HIV vaccine. This was substantiated by the lack
of detectable antibodies in the negative control mice. Using both
the FACS and ELISPOT analyses robust Gag-specific CD8
+ T
cell responses were observed (Figures 2 and 3). Interestingly, the
breath and magnitude of the cellular immune response detected
for pORT Gag 203 was stronger than that observed for the
positive control. Noteworthy was the Gag-specific cellular immune
response restimulated by pool 2 which was stronger than that by
pool 1 arguing for either response to at least two CTL- epitopes
being present in Gag or for one epitope localised at the ‘‘border’’
of the two pools. This observation concurs with previous studies
showing that Gag represents a major target of CTL responses in
HIV-1 infected patients and has a high density of epitopes [39].
This observation gives impetus to vaccine design strategies that
seek to elicit responses to a broad array of HIV-1 epitopes, and
suggest a particular focus on Gag [40]. Also, the consensus Tat
NG generated only moderate cellular immunity. It is commonly
accepted that the use of combinations of HIV proteins as vaccine
immunogens is more effective than a single antigen [22]. Given
this, the combination of a Gag and Tat based vaccine may be
reasonable. For the Env constructs (pORT Env NG2 and pORT
Env NG9) no cellular immune response could be detected
(Figures 2 and 3). However, the peptides used to detect cellular
immunity represent only a small fragment of the Env V3 region
and this experiment was restricted to a BALB/c mouse
background. Therefore, additional experiments to evaluate the
cellular immune responses against the Env constructs are planned.
Collectively, this study demonstrates that a CRF02_AG and G
based vaccine can stimulate humoral and cell mediated responses
and should be explored further for possible use as a candidate
vaccines. This provides a framework for the rational design of
vaccines against HIV-1 in regions of West and West-central
Africa.
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